Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | DAO | P14920 | 2/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.40 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | AGXT | P21549 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5460648 | 0.83 | TAAR1 (0.51) | TAAR1DAOIDO1AGXTMEN1 | |
| SCHEMBL6927695 | 0.80 | TAAR1 (0.57) | TAAR1SLC6A3DAOIDO1DRD2 | |
| SCHEMBL23732878 | 0.80 | TAAR1 (0.57) | TAAR1GPR84IDO1AGXT | |
| SCHEMBL10154041 | 0.79 | TAAR1 (0.52) | TAAR1PTGES2IDO1L3MBTL1 | |
| SCHEMBL6793104 | 0.78 | IDO1 (0.59) | TAAR1PTGES2IDO1MEN1KMT2A | |
| SCHEMBL2239914 | 0.77 | TAAR1 (0.53) | TAAR1SLC6A3DAOGPR84IDO1 | |
| SCHEMBL4881416 | 0.77 | TAAR1 (0.58) | TAAR1SLC6A3DAONR3C2IDO1 | |
| SCHEMBL775898 | 0.77 | TAAR1 (0.53) | TAAR1SLC6A3DAONR3C2IDO1 | |
| SCHEMBL10879373 | 0.75 | TSHR (0.51) | MEN1KMT2A | |
| SCHEMBL6988122 | 0.75 | TAAR1 (0.54) | TAAR1SLC6A3DAONR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165309-A1 | HETERO RING DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-28 | — | — | US | disclosed |
| WO-2010092962-A1 | HETERO RING DERIVATIVE | アステラス製薬株式会社 (JP) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165309-A1 | HETERO RING DERIVATIVE | IL2, PIK3R2, IL2RA | TAAR1 2247/4885SLC6A3 4731/4885DAO 2784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.